MCID: INT025
MIFTS: 38

Intermittent Explosive Disorder malady

Category: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs

Aliases & Classifications for Intermittent Explosive Disorder

About this section

Aliases & Descriptions for Intermittent Explosive Disorder:

Name: Intermittent Explosive Disorder 11 13 68
 
Explosive Personality Disorder 11 68

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 30


External Ids:

Disease Ontology11 DOID:12401
ICD1030 F60.3, F63.81
ICD9CM32 301.3, 312.34
MeSH39 D007174
NCIt45 C94332

Summaries for Intermittent Explosive Disorder

About this section
Disease Ontology:11 An impulse control disorder that involves the episodic inability to control violent impulses with a disproportionate degree of aggressiveness.

MalaCards based summary: Intermittent Explosive Disorder, also known as explosive personality disorder, is related to pyromania and coloboma of iris. An important gene associated with Intermittent Explosive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways are Overview of nanoparticle effects and Serotonergic synapse. Affiliated tissues include amygdala and brain, and related mouse phenotypes are homeostasis/metabolism and nervous system.

Wikipedia:71 Intermittent explosive disorder (sometimes abbreviated as IED) is a behavioral disorder characterized by... more...

Related Diseases for Intermittent Explosive Disorder

About this section

Diseases related to Intermittent Explosive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
idRelated DiseaseScoreTop Affiliating Genes
1pyromania11.0
2coloboma of iris10.2CRP, IL6
3apperceptive agnosia10.2CRP, HTR1A, SLC6A4
4tactile agnosia10.2SMOC1, SMUG1
5dry eye syndrome10.2HTR1A, HTR7, SLC6A4
6renpenning syndrome10.2HTR1A, HTR7, SLC6A4
7cutaneous sclerosis10.2CRP, IL6
8antisocial personality disorder10.2HTR1A, SMOC1
9tinea pedis10.1HTR1A, HTR7, SLC6A4
10human immunodeficiency virus infectious disease10.1CRP, IL6, SMUG1
11keratosis10.1HTR1A, HTR7, SLC6A4
12lichen disease10.1HTR1A, IL6, SLC6A4
13toxic myocarditis10.1ADRB1, CRP, IL6
14fallopian tube adenomatoid tumor10.1CRP, SMUG1
15abnormal pupillary function10.1HTR1A, HTR7
16stiff-person syndrome10.1CRP, IL6, SMUG1
17shoulder impingement syndrome10.1CRP, IL6
18chronic eosinophilic pneumonia10.1HTR1A, PRL, SLC6A4
19ellis-van creveld syndrome10.1CHRFAM7A, CHRNA7, HTR1A, SLC6A4
20unilateral multicystic dysplastic kidney10.1CRP, IL6
21nodular nonsuppurative panniculitis10.1CRP, IL6, SMOC1
22personality disorder10.0
23conjunctival pigmentation10.0HTR7, SLC6A4
24adrenal adenoma10.0CRP, IL6, NPY
25benign epilepsy with centrotemporal spikes10.0HTR1A, IL6, NPY, SLC6A4
26chronic conjunctivitis10.0CHRNA7, HTR1A, PRL, SLC6A4
27hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy10.0NPY, PRL, SLC6A4
28alzheimer disease 1710.0HTR1A, HTR7, PRL, SLC6A4
29hepatitis d10.0HTR1A, NPY, PRL, SLC6A4
30microcephaly 13, primary, autosomal recessive9.9GOLPH3, HTR1A, HTR7, SLC6A4
31body dysmorphic disorder9.9CRP, IL6, NPY, PRL
32breast hemangiopericytoma9.9CRP, IL6, PRL, SMOC1
33mucinous adenocarcinoma9.9GABRA2, NPY, PRL, SLC6A4
34autism spectrum disorder9.9HTR7, MFAP4, SLC6A4
35preeclampsia/eclampsia 59.8GABRA2, HTR1A, HTR7, NPY, SLC6A4
36obsessive-compulsive disorder9.8
37prader-willi syndrome9.8
38bipolar disorder9.8
39borderline personality disorder9.8
40obsessive-compulsive personality disorder9.8
41avoidant personality disorder9.8
42schizophrenia9.5CHRFAM7A, CHRNA7, CRP, HTR1A, HTR7, NPY
43luxation of globe7.9ADRB1, CGA, CHRFAM7A, CHRNA7, CRP, CTSH

Comorbidity relations with Intermittent Explosive Disorder via Phenotypic Disease Network (PDN):


Alzheimer DiseaseSchizophreniform Disorder
Acute Cystitis

Graphical network of the top 20 diseases related to Intermittent Explosive Disorder:



Diseases related to intermittent explosive disorder

Symptoms & Phenotypes for Intermittent Explosive Disorder

About this section

MGI Mouse Phenotypes related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053767.1ADRB1, CGA, CHRNA7, CRP, GABRA2, HTR1A
2MP:00036316.8CGA, CHRNA7, GABRA2, HTR1A, HTR7, IL6

Drugs & Therapeutics for Intermittent Explosive Disorder

About this section

Drugs for Intermittent Explosive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Guanfacineapproved, investigationalPhase 45929110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine (INN)
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
2
Naratriptanapproved, investigationalPhase 415143388-64-1, 121679-13-84440
Synonyms:
121679-13-8
AC-5013
AC1L1I6A
Amerge, Naramig,Naratriptan
BIDD:GT0312
C07792
CHEBI:7478
CHEMBL1278
CID4440
Colatan
D08255
DB00952
InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H
L000432
 
LS-83062
MolPort-005-932-823
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
NCGC00181786-01
Naramig
Naramig (TN)
Naratriptan (INN)
Naratriptanum
S1488_Selleck
UNII-QX3KXL1ZA2
naratriptan
naratriptanum
3Adrenergic AgentsPhase 45352
4Adrenergic alpha-2 Receptor AgonistsPhase 4980
5Neurotransmitter AgentsPhase 4, Phase 3, Phase 218340
6Adrenergic AgonistsPhase 43027
7Adrenergic alpha-AgonistsPhase 41734
8Antihypertensive AgentsPhase 44207
9Vasoconstrictor AgentsPhase 4, Phase 1, Phase 22122
10Serotonin AgentsPhase 4, Phase 3, Phase 23156
11
SerotoninPhase 4, Phase 3, Phase 2362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
12Serotonin 5-HT1 Receptor AgonistsPhase 4209
13
Risperidoneapproved, investigationalPhase 3492106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
14
DopamineapprovedPhase 3383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
15Serotonin AntagonistsPhase 31409
16Tranquilizing AgentsPhase 34265
17Psychotropic DrugsPhase 3, Phase 26430
18Dopamine AntagonistsPhase 31093
19Central Nervous System DepressantsPhase 313403
20Antipsychotic AgentsPhase 32401
21Dopamine AgentsPhase 33836
22
Fluoxetineapproved, vet_approvedPhase 223854910-89-33386
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
AKOS003663021
Adofen
Animex-On
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
Bio-0787
Biomol-NT_000152
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetine [USAN:INN:BAN]
Fluoxetinum
 
Fluoxetinum [INN-Latin]
Fluoxétine
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
LS-31040
Lilly-110140
Lopac0_000558
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
SPBio_001815
SPBio_002382
STK734483
Sarafem
SpecPlus_000723
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
Spectrum_001679
TL8003595
UNII-01K63SUP8D
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
fluoxetine
fluoxetine (Prozac)
nchembio.534-comp2
23Antidepressive Agents, Second-GenerationPhase 21311
24Cytochrome P-450 CYP2D6 InhibitorsPhase 2727
25Neurotransmitter Uptake InhibitorsPhase 23521
26Serotonin Uptake InhibitorsPhase 21587
27Antidepressive AgentsPhase 22736
28Cytochrome P-450 Enzyme InhibitorsPhase 23917
29Natriuretic AgentsPhase 1, Phase 21697
30CoagulantsPhase 1, Phase 21500
31Arginine VasopressinPhase 1, Phase 2299
32HemostaticsPhase 1, Phase 21443
33HormonesPhase 1, Phase 214415
34SRX246Phase 1, Phase 27
35VasopressinsPhase 1, Phase 2294

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive DisorderUnknown statusNCT02048241Phase 4
2Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment OrderTerminatedNCT00282165Phase 4
3Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.CompletedNCT00399698Phase 3
4Psychotherapy for Intermittent Explosive DisorderCompletedNCT00667212Phase 2
5Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive DisorderCompletedNCT02055638Phase 1, Phase 2
6A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive DisorderCompletedNCT00078754Phase 2
7A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IEDCompletedNCT00127400Phase 2

Search NIH Clinical Center for Intermittent Explosive Disorder

Genetic Tests for Intermittent Explosive Disorder

About this section

Anatomical Context for Intermittent Explosive Disorder

About this section

MalaCards organs/tissues related to Intermittent Explosive Disorder:

36
Amygdala, Brain

Publications for Intermittent Explosive Disorder

About this section

Articles related to Intermittent Explosive Disorder:

(show top 50)    (show all 82)
idTitleAuthorsYear
1
Amygdala hyperactivation to angry faces in intermittent explosive disorder. (27145325)
2016
2
Social cognition in Intermittent Explosive Disorder and aggression. (27621104)
2016
3
Negative urgency and reward/punishment sensitivity in intermittent explosive disorder. (27155024)
2016
4
Prevalence of DSM-IV Intermittent Explosive Disorder in Black Adolescents: Findings From the National Survey of American Life, Adolescent Supplement. (27078052)
2016
5
Comorbid intermittent explosive disorder and posttraumatic stress disorder: Clinical correlates and relationship to suicidal behavior. (27624432)
2016
6
The cross-national epidemiology of DSM-IV intermittent explosive disorder. (27572872)
2016
7
Development of a screening questionnaire for DSM-5 intermittent explosive disorder (IED-SQ). (28088746)
2016
8
Differential fMRI BOLD responses in amygdala in intermittent explosive disorder as a function of past Alcohol Use Disorder. (27693977)
2016
9
Substance use disorders: Relationship with intermittent explosive disorder and with aggression, anger, and impulsivity. (27442963)
2016
10
Defense styles in Intermittent Explosive Disorder. (27086223)
2016
11
Single Case Study: Neuropsychological Functioning in a Patient Diagnosed with Intermittent Explosive Disorder Pre and Post Neurosurgery. (27161981)
2016
12
White Matter Integrity Reductions in Intermittent Explosive Disorder. (27206265)
2016
13
Verbal versus physical aggression in Intermittent Explosive Disorder. (25534757)
2015
14
The experience of aggressive outbursts in Intermittent Explosive Disorder. (25541537)
2015
15
The coherence and correlates of intermittent explosive disorder amongst West Papuan refugees displaced to Papua New Guinea. (25754605)
2015
16
Effects of Escitalopram Administration on Face Processing in Intermittent Explosive Disorder: An fMRI Study. (26105140)
2015
17
Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder. (26277033)
2015
18
Emotional intelligence and impulsive aggression in Intermittent Explosive Disorder. (25477263)
2015
19
Emotion regulation deficits in intermittent explosive disorder. (27539871)
2015
20
Intermittent Explosive Disorder and aversive parental care. (25064384)
2014
21
Emotion regulation deficits in intermittent explosive disorder. (25403171)
2014
22
Relationship between psychopathy, aggression, anger, impulsivity, and intermittent explosive disorder. (24760575)
2014
23
Doing Psychiatry Right: A Case of Severe Avoidant Personality Disorder with Obsessive-compulsive Personality Disorder, Obsessive Compulsive Disorder, Intermittent Explosive Disorder and Sexual Paraphilias. (25035563)
2014
24
Validity of the new A1 and A2 criteria for DSM-5 intermittent explosive disorder. (24321204)
2014
25
Intermittent explosive disorder: a study in personalized psychopharmacotherapy. (24441311)
2014
26
Self-harm behavior among individuals with intermittent explosive disorder and personality disorders. (25300440)
2014
27
History of childhood maltreatment in intermittent explosive disorder and suicidal behavior. (24935900)
2014
28
Elevated Plasma Oxidative Stress Markers in Individuals with Intermittent Explosive Disorder and Correlation with Aggression in Humans. (24582164)
2014
29
Common and distinct neural correlates of inhibitory dysregulation: stroop fMRI study of cocaine addiction and intermittent explosive disorder. (25106072)
2014
30
Intermittent explosive disorder: associations with PTSD and other Axis I disorders in a US military veteran sample. (24907536)
2014
31
Intermittent explosive disorder amongst women in conflict affected Timor-Leste: associations with human rights trauma, ongoing violence, poverty, and injustice. (23950885)
2013
32
Achieving convergence between a community-based measure of explosive anger and a clinical interview for intermittent explosive disorder in Timor-Leste. (23835102)
2013
33
Elevated Plasma Inflammatory Markers in Individuals With Intermittent Explosive Disorder and Correlation With Aggression in Humans. (24352431)
2013
34
Intermittent explosive disorder and DSM-5: a flawed conceptualization of pathological anger. (23719736)
2013
35
The prevalence and correlates of intermittent explosive disorder in Iraq. (22443168)
2012
36
Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5. (22535310)
2012
37
Striatal activity in borderline personality disorder with comorbid intermittent explosive disorder: sex differences. (22464337)
2012
38
Intermittent explosive disorder in the National Comorbidity Survey Replication Adolescent Supplement. (22752056)
2012
39
The relationship between childhood exposure to trauma and intermittent explosive disorder. (22464047)
2012
40
Genomic architecture of aggression: rare copy number variants in intermittent explosive disorder. (21812102)
2011
41
Epidemiological aspects of intermittent explosive disorder in Japan; prevalence and psychosocial comorbidity: findings from the World Mental Health Japan Survey 2002-2006. (20709410)
2011
42
Intermittent explosive disorder: development of integrated research criteria for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. (21295216)
2011
43
Treating intermittent explosive disorder. Emerging data show medication and cognitive behavioral therapy may help some patients. (21786470)
2011
44
Inverse relationship between numbers of 5-HT transporter binding sites and life history of aggression and intermittent explosive disorder. (19767013)
2010
45
Expert witness claimed that a defendant had "intermittent explosive disorder," GMC hears. (21147742)
2010
46
A family history study of intermittent explosive disorder. (20488459)
2010
47
Latent structure of intermittent explosive disorder in an epidemiological sample. (20064645)
2010
48
Deep brain stimulation of the orbitofrontal projections for the treatment of intermittent explosive disorder. (20672913)
2010
49
Proactive, reactive, and romantic relational aggression in adulthood: measurement, predictive validity, gender differences, and association with Intermittent Explosive Disorder. (19822329)
2010
50
Unhealthy aggression: intermittent explosive disorder and adverse physical health outcomes. (20496987)
2010

Variations for Intermittent Explosive Disorder

About this section

Expression for genes affiliated with Intermittent Explosive Disorder

About this section
Search GEO for disease gene expression data for Intermittent Explosive Disorder.

Pathways for genes affiliated with Intermittent Explosive Disorder

About this section

Pathways related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Overview of nanoparticle effects42
9.8CRP, IL6
2
Serotonergic synapse34
9.6HTR1A, HTR7, SLC6A4
3
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics56
9.6HTR1A, HTR7, SLC6A4
4
Regulation of lipolysis in adipocytes34
9.6ADRB1, CGA, NPY
5
Monoamine GPCRs42
Show member pathways
9.5ADRB1, HTR1A, HTR7
6
Glucocorticoid receptor regulatory network42
9.3CGA, IL6, PRL
7
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways42
9.1CHRFAM7A, CHRNA7, HTR1A, IL6, SLC6A4
8
Peptide ligand-binding receptors60
Show member pathways
7.5ADRB1, CGA, CHRNA7, GABRA2, HTR1A, HTR7

GO Terms for genes affiliated with Intermittent Explosive Disorder

About this section

Biological processes related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of organ growthGO:004662110.8CGA, SLC6A4
2negative regulation of lipid storageGO:001088810.5CRP, IL6
3adenylate cyclase-inhibiting serotonin receptor signaling pathwayGO:000719810.5HTR1A, HTR7
4behaviorGO:000761010.5HTR1A, NPY
5circadian rhythmGO:000762310.0HTR7, PRL, SLC6A4
6positive regulation of JAK-STAT cascadeGO:00464279.8IL6, PRL
7positive regulation of gene expressionGO:00106289.8CRP, CTSH, IL6, SLC6A4
8vasoconstrictionGO:00423109.6HTR1A, HTR7, SLC6A4
9positive regulation of cell proliferationGO:00082849.1CGA, CHRNA7, CTSH, HTR1A, IL6, PRL

Molecular functions related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular ligand-gated ion channel activityGO:000523010.0CHRFAM7A, CHRNA7, GABRA2
2serotonin bindingGO:00513789.8HTR1A, HTR7
3hormone activityGO:00051799.5CGA, NPY, PRL

Sources for Intermittent Explosive Disorder

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z